How should I evaluate and manage a patient with an elevated parathyroid hormone level?

Evaluation and Management of Elevated PTH

Begin by measuring serum calcium, 25-hydroxyvitamin D, serum phosphorus, and estimated glomerular filtration rate (eGFR) simultaneously—these four tests will determine whether you are dealing with primary hyperparathyroidism, secondary hyperparathyroidism, or normocalcemic primary hyperparathyroidism. 1

---

Initial Diagnostic Algorithm

Step 1: Measure Serum Calcium (Corrected for Albumin)

• If calcium is elevated (>10.2 mg/dL): This indicates primary hyperparathyroidism when PTH is elevated or inappropriately normal (fails to suppress below 20 pg/mL). 1, 2
• If calcium is normal (8.6–10.2 mg/dL): Proceed to differentiate between secondary hyperparathyroidism and normocalcemic primary hyperparathyroidism. 1, 3
• If calcium is low or normal with elevated PTH: This suggests secondary hyperparathyroidism. 1, 4

Critical pitfall: Always correct total calcium for albumin; if albumin is abnormal, measure ionized calcium (normal: 4.65–5.28 mg/dL) to avoid misclassification. 2

---

Step 2: Assess Vitamin D Status

• Measure 25-hydroxyvitamin D in every patient with elevated PTH. Vitamin D deficiency (<30 ng/mL) is the most common and most frequently missed reversible cause of secondary hyperparathyroidism. 1, 3
• If 25-OH vitamin D is <30 ng/mL: Supplement with cholecalciferol or ergocalciferol to achieve levels ≥30 ng/mL before pursuing any other intervention or diagnosis. 1, 3
• Vitamin D–replete individuals have PTH concentrations approximately 20% lower than those with unknown vitamin D status, so reference ranges must be interpreted accordingly. 2

---

Step 3: Evaluate Kidney Function

• Measure serum creatinine and calculate eGFR. PTH rises when eGFR falls below 60 mL/min/1.73 m², making chronic kidney disease a key differential diagnosis. 1, 3
• In adults older than 60 years, age-related decline in GFR is the most frequent cause of elevated PTH with normal calcium. 3
• If eGFR is <60 mL/min/1.73 m²: Proceed to CKD-related secondary hyperparathyroidism management (see below). 3

---

Step 4: Measure Serum Phosphorus

• Low or low-normal phosphorus suggests primary hyperparathyroidism. 1, 2
• Elevated phosphorus suggests CKD-related secondary hyperparathyroidism. 1, 3

---

Step 5: Exclude Other Causes of Secondary Hyperparathyroidism

• Assess dietary calcium intake: Confirm the patient meets age-related recommended dietary allowance (1,000–1,200 mg/day for adults). Inadequate intake can cause secondary hyperparathyroidism. 1, 3
• Review medications: Lithium salts, thiazide diuretics, and antiresorptive osteoporosis therapies can elevate PTH. 5
• Evaluate for malabsorption: Gastrointestinal conditions (e.g., celiac disease, inflammatory bowel disease, bariatric surgery) impair calcium absorption and cause secondary hyperparathyroidism. 1, 6
• Measure 24-hour urinary calcium or spot urine calcium/creatinine ratio: Renal calcium leak (hypercalciuria) can cause secondary hyperparathyroidism. 1, 5

---

Management Based on Underlying Cause

A. Primary Hyperparathyroidism (Elevated Calcium + Elevated/Inappropriately Normal PTH)

Refer to endocrinology and an experienced parathyroid surgeon for surgical evaluation. 1, 2

Indications for Parathyroidectomy:

• Corrected calcium >1 mg/dL above upper limit of normal 1, 2
• Age <50 years 1, 6
• eGFR <60 mL/min/1.73 m² 1, 2
• Osteoporosis (T-score ≤−2.5 at any site) 1
• History of nephrolithiasis or nephrocalcinosis 1, 6
• 24-hour urinary calcium >300 mg 1
• Symptomatic disease (e.g., bone pain, kidney stones, neurocognitive symptoms) 1, 6

Medical Management for Non-Surgical Candidates:

• Maintain normal calcium intake (1,000–1,200 mg/day); avoid high or low calcium diets. 2
• Ensure 25-OH vitamin D ≥20 ng/mL with supplementation if needed. 1
• Monitor serum calcium every 3 months. 2

Critical pitfall: Do not order parathyroid imaging (ultrasound, sestamibi scan) before confirming biochemical diagnosis; imaging is for surgical planning, not diagnosis. 2

---

B. Secondary Hyperparathyroidism (Normal/Low Calcium + Elevated PTH)

If Vitamin D Deficiency (<30 ng/mL):

• Supplement with cholecalciferol or ergocalciferol to achieve 25-OH vitamin D ≥30 ng/mL. 1, 3
• Recheck PTH after 3 months of vitamin D repletion; if PTH normalizes, vitamin D deficiency was the cause. 3
• Monitor serum calcium and phosphorus at least every 3 months during supplementation; discontinue vitamin D immediately if calcium exceeds 10.2 mg/dL. 2

If CKD-Related (eGFR <60 mL/min/1.73 m²):

Step 1: Correct Reversible Factors Before Any PTH-Lowering Therapy

• Correct vitamin D deficiency (target 25-OH vitamin D ≥30 ng/mL). 3
• Correct hyperphosphatemia with dietary phosphate restriction as the first-line intervention. 3
• Ensure adequate calcium intake (1,000–1,200 mg/day). 3

Step 2: Avoid Routine Use of Active Vitamin D Analogs

• Do not use calcitriol or other active vitamin D analogs (alfacalcidol, doxercalciferol) in CKD stages 3a–5 not on dialysis. These increase the risk of hypercalcemia and adynamic bone disease. 3
• Reserve active vitamin D only for severe, progressive hyperparathyroidism (PTH persistently >300 pg/mL with upward trend) in CKD stages G4–G5. 3

Step 3: Monitoring Schedule

• CKD G3a–G3b: Measure calcium and phosphorus every 6–12 months; measure PTH every 3–6 months. 1, 3
• CKD G4: Measure calcium and phosphorus every 3–6 months; measure PTH every 3–6 months. 1, 3
• CKD G5: Measure calcium and phosphorus every 1–3 months; measure PTH every 3 months. 1, 3

Step 4: Consider Cinacalcet for Refractory Cases

• In dialysis patients with persistent PTH elevation despite correction of reversible factors, cinacalcet can reduce PTH and calcium-phosphorus product. 7
• Caution: Cinacalcet is contraindicated in hypocalcemia and is associated with increased QT intervals; monitor closely. 8, 7

Critical pitfall: Do not aim to suppress PTH to the normal range in CKD; mild hyperparathyroidism can be protective against adynamic bone disease. 3

---

C. Normocalcemic Primary Hyperparathyroidism (Normal Calcium + Persistently Elevated PTH After Excluding Secondary Causes)

Normocalcemic primary hyperparathyroidism is defined by persistently elevated PTH with consistently normal albumin-corrected serum calcium after exclusion of all secondary causes. 2

Diagnostic Criteria:

• 25-OH vitamin D ≥20 ng/mL (to exclude vitamin D deficiency) 2
• eGFR ≥60 mL/min/1.73 m² (to exclude CKD) 2
• Adequate dietary calcium intake (1,000–1,200 mg/day) 2
• No medications causing secondary hyperparathyroidism 2

Management:

• Normocalcemic primary hyperparathyroidism is not benign; it carries a risk profile comparable to hypercalcemic primary hyperparathyroidism. 2
• Refer to endocrinology and an experienced parathyroid surgeon if the patient meets surgical indications (e.g., 24-hour urinary calcium >300 mg, osteoporosis, neurocognitive symptoms, patient preference for definitive treatment). 2
• For non-surgical candidates, maintain 25-OH vitamin D ≥20 ng/mL and monitor serum calcium every 3–6 months. 2

---

Special Considerations

PTH Assay Variability

• PTH results can vary by up to 47% between different assay generations; always use assay-specific reference ranges. 8, 2
• PTH should be measured in EDTA plasma (not serum) and kept at 4°C for optimal stability. 8, 2
• Biotin supplementation interferes with PTH immunoassays; patients should discontinue biotin at least 72 hours before blood draw. 2

Biological Variation

• Within-subject biological variation of PTH is approximately 20% in healthy individuals; a change exceeding 54% is required to be clinically meaningful. 2
• Repeat PTH measurement after 3 months to confirm persistent elevation and account for inherent variability. 3

Age-Related PTH Elevation

• In elderly patients (>60 years), age-related decline in GFR is the most frequent cause of elevated PTH with normal calcium; interpret results using age-adjusted reference ranges. 2, 3

Severe Hypercalcemia (Calcium >14 mg/dL or Ionized Calcium >5.9 mg/dL)

• Initiate aggressive intravenous hydration with isotonic normal saline immediately. 2
• Administer intravenous bisphosphonates (zoledronic acid or pamidronate) as first-line pharmacologic therapy. 2
• Monitor ionized calcium every 4–6 hours during acute treatment. 2
• If PTH is suppressed (<20 pg/mL) and PTHrP is elevated, suspect malignancy-associated hypercalcemia; perform immediate comprehensive imaging (chest CT, abdominal/pelvic CT or MRI, PET-CT) and oncology consultation. 2

---

Common Pitfalls to Avoid

• Do not diagnose primary hyperparathyroidism without first confirming adequate vitamin D status (≥30 ng/mL) and sufficient calcium intake. Vitamin D deficiency is the most common reversible cause of elevated PTH. 1, 3
• Do not use calcitriol or active vitamin D analogs in primary hyperparathyroidism or early CKD (G3a–G3b). They increase intestinal calcium absorption and can exacerbate hypercalcemia. 2, 3
• Do not order parathyroid imaging before confirming biochemical diagnosis. Imaging is for surgical planning, not diagnosis. 2
• Do not attribute normocalcemic PTH elevation to primary hyperparathyroidism in patients >60 years without excluding age-related GFR decline. 3
• Do not aim to suppress PTH to the normal range in CKD patients. Mild hyperparathyroidism can be protective against adynamic bone disease. 3